Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

Eligibility Criteria

• * subject has given written informed consent;
• * Premenopausal women 35 to 42 years of age at the time of consent (at least 35 \[including day of birthday\] and no more than 42 \[up to the day before their 43rd birthday\]);
• * Valid indication for IVF treatment (i.e. history of infertility according to ASRM definition, single women or same-sex couples);
• * Consistent, regular spontaneous ovulatory menstrual cycle with normal length (24-38 days included);
• * Body mass index (BMI) \< 38 kg/m2;
• * Subject with at least one euploid frozen blastocyst from a previous IVF treatment cycle;
• * Less than 3 previous consecutive euploid blastocyst transfers without a life birth;
• * Baseline Follicle Stimulating Hormone (FSH) \< 15 mIU/mL, and Anti Muellerian Hormone (AMH) \>0.7 ng/mL (within 6 months from screening for subjects requiring a stimulation cycle to obtain a euploid embryo); and Estradiol (E2) \< 90 pg/mL and Progesterone (P4)\< 1.5 ng/mL at Visit 1 (for all subjects);
• * Semen used during IVF(for subjects requiring a stimulation cycle to obtain a euploid embryo) was produced by ejaculation (not surgically derived sperm) from either the partner or from a sperm donor. Donor must be 18-40 years of age at the time of collection and compliant with 21 Code of Regulations (CFR) section 1271 Subpart C;
• * Hysterosalpingography, hysteroscopy, 3D ultrasound or sonohysterogram documenting a normal uterine cavity within the last year;
• * Normal cervical cytology/High Risk human papillomavirus (HPV) testing per American College of Obstetricians and Gynecologists guidelines.
• * Oligo or anovulation (spontaneous menses \> 39 days apart);
• * Breastfeeding or Pregnancy;
• * Contraindication to pregnancy (i.e. an active, uncontrolled clinically significant medical condition or abnormality of the sexual organs determined by the provider);
• * Known family history of major congenital anomalies;
• * Moderate to severe current endometriosis (stage 3 or 4);
• * Presence of a unilateral or bilateral hydrosalpinx that communicates with the uterus, that has not been ligated prior to treatment;
• * Recurrent pregnancy loss (RPL) as defined by the American Society of Reproductive Medicine (ASRM) as two or more consecutive failed clinical pregnancies;
• * Presence of a submucosal or intramural fibroid \> 4 cm which distorts the uterine cavity or are \> 5 cm in diameter;
• * Untreated uterine pathology that could impair embryo implantation (i.e. scarring/Asherman's syndrome or intra uterine polyps \> 1 cm in size);
• * Type 1 or 2 diabetes mellitus based on American Diabetes Association (ADA) criteria3;
• * Uncontrolled adrenal or thyroid dysfunction;
• * History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;
• * Subjects with hepatic impairment (liver function tests \> 2x upper limit of normal);
• * Subjects with renal impairment (estimated creatinine clearance \<60 mL/min/1.73 m2);
• * History of an active or treated autoimmune disease (i.e. systemic lupus erythematosus);
• * History of arterial disease (i.e. Prior or active thrombophlebitis, thromboembolic disorder or known thrombophilia);
• * Neoplasias (current) or history of neoplasia that may be responsive to progesterone;
• * High grade cervical dysplasia;
• * Undiagnosed vaginal bleeding (i.e. at the time of screening);
• * Use of donor eggs or plans to use a gestational carrier;
• * Use of endometrial receptivity array (ERA) test to postpone or anticipate the embryo transfer (ET) day;
• * Use of epididymal, testicular , electro-ejaculated or chemotherapy exposed sperm;
• * Known allergy to progesterone preparations or their excipients;
• * Current dependence on alcohol, tobacco (must not be smoking/using tobacco x 2 months before the study) or drugs or psychotropic medications labeled as Pregnancy Categories D and X;
• * Use of concomitant medications within 1 month previous the start of the FET cycle preparation up to gestational week 12 that might interfere with the study evaluation (use of insulin sensitizing agents, vaginal medications/preparations, any drugs for luteal support other than those specified in the protocol, aspirin, any hormonal treatment, with the exception of levothyroxine);
• * Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months-